ASGCT News

ASGCT Members Provide Recommendations During FDA Liaison Meeting

ASGCT Staff | November 23, 2021

Society members spoke on three significant topics in the field during the Nov. 8 liaison meeting.

Read Full Story

Gene Therapy Strategies for Diabetic Eye Diseases

Nachi Pendse, PhD | November 23, 2021

In this blog post, Patricia D’Amore, PhD, MBA; Sui Wang, PhD; and Nachi Pendse, PhD; shared some of their insights on how cell and gene therapy can help patient populations with diabetic eye disorders.

Read Full Story

Gene and Cell Therapies: A Breath of Fresh Air for Lung Cancer Treatment?

Eoghan J. Mulholland, PhD | November 18, 2021

To recognize Lung Cancer Awareness Month, Dr. Eoghan Mulholland describes how gene and cell therapies could eventually lead to the treatment and prevention of this disease.

Read Full Story

Submit Your Abstracts for the 25th Annual Meeting

ASGCT Staff | November 16, 2021

The call for abstracts is open through February 2, 2022.

Read Full Story

OTAT Announces Growth Program at ASGCT/FDA Liaison Meeting

ASGCT Staff | November 12, 2021

Learn about the new OTAT program and view presentation slides from ASGCT's fourth annual liaison meeting with the FDA this week.

Read Full Story

How to Access Today's Free Professional Development Café

ASGCT Staff | November 12, 2021

Join us from 1-3 p.m. (CT) for Staying Strong: You Are Not Alone.

Read Full Story

Learning About CRISPR from a Genome Editor

Kenji Rowel Lim | November 01, 2021

“We’re able to modify the genome now in ways that we simply could not imagine several years ago,” Ben Kleinstiver, PhD, told attendees during ASGCT's most recent Professional Development Café.

Read Full Story

Booster Shots Are Safe and Effective

Edith Pfister, PhD | October 29, 2021

The FDA recently authorized additional doses of the Pfizer, Moderna, and Johnson & Johnson vaccines for COVID-19.

Read Full Story

ASGCT Joins National Partnership to Accelerate Gene Therapy Development for Rare Diseases

ASGCT Staff | October 27, 2021

The new effort aims to make gene therapy more accessible by creating a development template that can be used repeatedly to expedite the delivery of novel therapies for many different genetic disorders.

Read Full Story

Read ASGCT's Third Quarter Landscape Analysis Field Report

ASGCT Staff | October 22, 2021

The third quarterly publication from ASGCT and Informa Pharma Intelligence, the Gene, Cell, & RNA Therapy Landscape report, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Read Full Story

ASGCT Symposium Catalyzes Discussions to Expand Reach of Gene Therapy in India

Savita Rangarajan, MD, and Jayandharan Rao, PhD | October 19, 2021

The goal of the Oct. 9 event was to explore how to facilitate gene therapy clinical research to ultimately expand patient access to therapies in India in the future.

Read Full Story

Paloma Giangrande, PhD, is Not Afraid to Push Herself Out of Her Comfort Zone

ASGCT Staff | October 18, 2021

The incoming editor-in-chief of Molecular Therapy Nucleic Acids will assume her role on January 1, 2022, replacing John Rossi, PhD.

Read Full Story

FDA Approves First CAR T-Cell Therapy for ALL

ASGCT Staff | October 14, 2021

This marks approval of a second disease indication for Tecartus, which received accelerated approval for the treatment of adults with r/r mantle cell lymphoma in July 2020.

Policy & Advocacy

Read Full Story

Policy Summit Speakers Offer Strategies to Deal With the Challenges of Accelerated Approval

ASGCT Staff | October 06, 2021

FDA's accelerated approval program allows for early approval of drugs and biologics that treat serious conditions with a lack of alternate treatments.

Policy Summit

Read Full Story

Engage Patients Early to Ensure Successful Therapeutics

Rachel Salzman, DVM | October 05, 2021

Increasing patient input will contribute to developing and delivering transformative medicines to benefit all of society, says Rachel Salzman, DVM.

Policy Summit

Read Full Story

On the Path to Treating Sickle Cell Disease, Greg Newby Relies on Colleagues and Lessons Learned

Nachi Pendse, PhD | October 01, 2021

Greg Newby, PhD, talks about his start in science, using base editing to treat sickle cell disease, and the future of gene therapy and base editing in the clinic.

Read Full Story